Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Topotecan hydrochloride

Topotecan hydrochloride

pharmaceutical raw materials
Topotecan hydrochloride structure

Topotecan hydrochloride 

structure
  • CAS No:

    119413-54-6

  • Formula:

    C23H23N3O5.ClH

  • Chemical Name:

    Topotecan hydrochloride

  • Synonyms:

    1H-Pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-,hydrochloride (1:1),(4S)-;1H-Pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-,monohydrochloride,(S)-;1H-Pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-,monohydrochloride,(4S)-;SKF 104864A;NSC 609669;Topotecan hydrochloride;Hycamtin;SKFS 104864A;Nogitecan hydrochloride;Topotecan chlorohydrate;(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[l,2-b]quinoline-3,14(4H,12H)-dione monohydrochloride;Xinze

  • Categories:

    Active Pharmaceutical Ingredients  >  Antineoplastic Agents

Description

Topotecan hydrochloride can enter the blood brain barrier. It has the same effect of oral and intravenous injection. The drug has low toxicity predictable bone marrow suppression, and other minor non-hematologic toxicity. Currently there are manufacturers, for clinical treatment of small cell lung cancer, ovarian cancer and other tumors.Topotecan hydrochloride inhibits the activity of topoisomerase I, which is required for DNA replication.


Irinotecan and topotecan are semisynthetic derivatives of the plant alkaloid camptothecin and are used as antineoplastic agents in the therapy of colorectal, ovarian and non-small cell lung cancer. Both irinotecan and topotecan are associated with an appreciable rate of serum enzyme elevations during therapy, and irinotecan has been implicated in causing steatohepatitis when given as cyclic anticancer therapy.|Topotecan Hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Camptothecin is a cytotoxic quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.|An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.

Topotecan hydrochloride Basic Attributes

457.91

421.163757

1308068-626-2

956S425ZCY

759263|609699

DTXSID1045952

C2828

L01CE01

29420000

Characteristics

103

2.64880

White Crystalline Solid

1.5±0.1 g/cm3

215 °C (decomp)

782.9ºC at 760mmHg

427.3±32.9 °C

1.734

Refrigerator

8.13E-26mmHg at 25°C

211.2 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Safety Information

25-36/37/38-46

26-36/37/39-45

T

P201, P202, P260, P261, P264, P270, P271, P273, P280, P281, P301+P310, P301+P312, P302+P352, P304+P340, P305+P351+P338, P307+P311, P308+P313, P312, P314, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, P501

H300

|Danger|H300 (33.33%): Fatal if swallowed [Danger Acute toxicity, oral]|P201, P202, P260, P261, P264, P270, P271, P273, P280, P281, P301+P310, P301+P312, P302+P352, P304+P340, P305+P351+P338, P307+P311, P308+P313, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 6 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Chemotherapy with irinotecan and topotecan in combination with other agents is associated with serum enzyme elevations in up 15% of patients depending upon the dose, other agents used, the frequency of monitoring and degree of elevation that is reported. The ALT elevations are usually asymptomatic and transient and may resolve without dose modification. Marked elevations occur in 1% to 4% of patients, but rarely require dose modification. Genetic variants in hepatic transporters and metabolic enzymes have been associated with predisposition to irinotecan toxicity, including OATP 1B1 (SLC01B1), UGT1A1 and CYP 3A4. However, the major toxicities of irinotecan are hematologic and diarrhea, and liver test elevations are rare causes of drug interruption or dose modification.

Drug Information

Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.|Drug: Topotecanhydrochloride

Irinotecan and topotecan are semisynthetic derivatives of the plant alkaloid camptothecin and are used as antineoplastic agents in the therapy of colorectal, ovarian and non-small cell lung cancer. Both irinotecan and topotecan are associated with an appreciable rate of serum enzyme elevations during therapy, and irinotecan has been implicated in causing steatohepatitis when given as cyclic anticancer therapy.

Antineoplastic Agents

Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)

9 Dimethylaminomethyl 10 hydroxycamptothecin

Topotecan hydrochloride Use and Manufacturing

Uses

A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic. Topotecan hydrochloride is a chemotherapy agent that is a topoisomerase 1 inhibitor.

Human drugs -> Hycamtin -> EMA Drug Category|Antineoplastic agents -> Human pharmacotherapeutic group|Human drugs -> Rare disease (orphan)|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:457.9
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:3
Exact Mass:457.1404486
Monoisotopic Mass:457.1404486
Topological Polar Surface Area:103
Heavy Atom Count:32
Complexity:867
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

This drug is an inhibitor of topoisomerase I. It can bind to the topoisomerase I-DNA complex and prevent the reconnection of single-stranded DNA breaks. It is a specific drug for the S phase of the cell cycle. By interacting with the replication enzyme to produce double-stranded DNA damage, mammalian cells cannot effectively repair these interruptions, thereby exerting a cytotoxic effect. Preclinical in vivo tests have shown significant efficacy in a variety of animal transplanted tumors.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • EMCURE PHARMACEUTICALS LTD

    United States United States
    Active
  • NOVARTIS PHARMACEUTICALS CORP

    United States United States
    Active
  • SCINOPHARM TAIWAN, LTD.

    Taiwan, China Taiwan, China
    Active

Recommended Suppliers of Topotecan hydrochloride

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.